Catalent, Inc.’s $139 Million Acquisition of Juniper Pharmaceuticals, Inc.

Goodwin advised Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) on its definitive agreement with Catalent, Inc., for Catalent to acquire all of the outstanding shares of Juniper at…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Ambrogio Visconti

This content is for Standard 1 Year members only.
Login Join Now